Treatment of acute granulocytic leukemias.
D000328:Adult; D000367:Age Factors; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001772:Blood Cell Count; D001792:Blood Platelets; D001856:Bone Marrow Examination; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006321:Heart / Q000187:drug effects; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D006835:Hydrazones / Q000627:therapeutic use; D007275:Injections, Intravenous; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D007958:Leukocyte Count
D000970:Antineoplastic Agents; D006835:Hydrazones; D003561:Cytarabine; D004317:Doxorubicin; D003630:Daunorubicin